Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Since the first biomarker of myocardial necrosis was described in 1954, cardiac-specific biomarkers have been increasingly identified. This, coupled with dramatic evolution in assay technology and resultant highly sensitive assays, has rendered a remarkable transformation in the medical use of biomarkers. Initially used to aid in diagnosis of myocardial infarction, newer biomarkers of inflammation, plaque instability, and ischemia may complement biomarkers of necrosis by providing tools to diagnose impending myocardial necrosis before irreversible damage occurs, and offering additional information for risk stratification. Importantly, biomarkers of different processes may be combined to enhance risk stratification above that of any single marker.
- LaDue JS, Wroblewski F, Karmen A: Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science 1954, 120:497–499. CrossRef
- Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000, 36:959–969. This is a consensus document reflecting many international views. It emphasizes troponin testing in the revised definition of MI secondary to the sensitivity and prognostic ability of troponin. Furthermore, it addresses standards of troponin assays and references for precision and accuracy. CrossRef
- Kontos MC, Fritz LM, Anderson FP, et al.: Impact of the troponin standard on the prevalence of acute myocardial infarction. Am Heart J 2003, 146:446–452. CrossRef
- Ottani F, Galvani M, Nicolinin FA, et al.: Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000, 140:917–927. CrossRef
- Heidenreich PA, Alloggiamento T, Melsop K, et al.: The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001, 38:478–485. CrossRef
- Rao SV, Ohman EM, Granger CB, et al.: Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. Am J Cardiol 2003, 91:936–940. CrossRef
- Dokainish H, Pillai M, Murphy SA, et al.: Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005, 45:19–24. CrossRef
- Aviles RJ, Askari AT, Lindahl B, et al.: Troponin T levels in patients with ACS with or without renal dysfunction. N Engl J Med 2002, 346:2047–2052. CrossRef
- Newby LK, Christenson RH, Ohman EM, et al., for the GUSTOIIa investigators: The value of serial troponin T measurements for early and late risk stratification in patients with acute coronary syndrome. Circulation 1998, 98:1853–1859.
- Newby LK, Ohman EM, Christenson RH, et al.: Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T positive status: the PARAGON B troponin T substudy. Circulation 2001, 103:2891–2896.
- Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein IIb/IIIA inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002, 359:189–198. This reference combined all major randomized clinical trials of GP IIb/IIIa inhibitors used in ACS in a meta-analysis. The data demonstrate treatment benefit from GP IIb/IIIa inhibitors in those that were troponin-positive at baseline. CrossRef
- Morrow DA, Cannon CP, Rifai N, et al.: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001, 286:2405–2412. CrossRef
- Wallentin L, Lagerqvist B, Husted S, et al.: Outcome at one year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the Frisc II invasive randomized trial. Lancet 2000, 356:9–16. CrossRef
- McCord J, Nowak RM, McCullough PA, et al.: Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001, 104:1483–1488.
- de Lemos JA, Morrow DA, Gibson CM, et al.: The prognostic value of serum myoglobin in patients with non-ST elevation acute coronary syndromes. Results form the TIMI 11B and Tactics-TIMI 18 studies. J Am Coll Cardiol 2002, 40:238–244. CrossRef
- Haverkate F, Thompson SG, Pyke SD, et al.: Production of Creactive protein and the risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349:462–466. CrossRef
- Heeschen C, Hamm CW, Bruemmer J, Simoons ML, for the CAPTURE investigators: Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol 2000, 35:1535–1542. CrossRef
- Morow DA, Rifai N, Antman EM, et al.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndrome: a TIMI 11A substudy. J Am Coll Cardiol 1998, 31:1460–1465. CrossRef
- Lindahl B, Toss H, Siegbahn A, et al.: Markers of myocardial damage and inflammation in relation to long term morality in unstable coronary artery disease. N Engl J Med 2000, 342:1139–1147. CrossRef
- Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/ CRP Evaulation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:53–70.
- Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998, 98:839–844.
- Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-Reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29–38. CrossRef
- Ridker PM, Rifai N, Clearfield M, et al.: Measurements of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959–1965. This subanalysis from AFCAPS/TexCAPS demonstrates CRP lowering with statins independent of cholesterol levels. Additionally, statin therapy results in a greater clinical benefit when the levels of CRP are elevated, regardless of LDL cholesterol level. CrossRef
- Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20–28. This substudy of PROVE IT demonstrated that among patients with ACS, those with lower levels of CRP have better clinical outcomes than those with higher levels, independent of the level of LDL cholesterol lowering achieved. CrossRef
- Lindmark E, Diderholm E, Wallentin L, Siegbahn A: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001, 286:2107–2113. This reference found that IL-6 can discriminate ACS patients who preferentially will benefit from an early invasive strategy. CrossRef
- Mach F, Schonbeck U, Bonnefoy JY, et al.: Activation of monocyte/macrophage function related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and RF. Circulation 1997, 96:396–399.
- Aukrust P, Muller F, Ueland T, et al.: Enhanced levels of soluble and membrane bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndrome. Circulation 1999, 100:614–620.
- Varo N, de Lemos JA, Libby P, et al.: Soluble CD40L. Risk prediction after acute coronary syndromes. Circulation 2003, 108:1049–1052. CrossRef
- Heeschen C, Dimmeler S, Hamm CW, et al.: Soluble CD40 ligand in acute coronary syndrome. N Engl J Med 2003, 348:1104–1111. CrossRef
- Kinlay S, Schwartz GG, Olsson AG, et al.: Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events after an Acute Coronary Syndrome Associated with High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004, 110:386–391. CrossRef
- Baldus S, Heeschen C, Meinertz T, et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440–1445. CrossRef
- Brennan ML, Penn MS, Van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595–1604. CrossRef
- Bayes-Genis A, Conover CA, Overgaard MT, et al.: Pregnancyassociated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001, 345:1022–1029. CrossRef
- Heeschen C, Dimmeler S, Hamm CW, et al.: Pregnancyassociated plasma protein-A levels in patients with acute coronary syndromes. J Am Coll Card 2005, 45:229–237. CrossRef
- Sagnella GA: Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 2001, 38:83–93. CrossRef
- Shapiro BP, Chen HH, Burnett JC, Redfield MM: Use of BNP to aid in the diagnosis of heart failure. Mayo Clin Proc 2003, 78:481–486. CrossRef
- McCullough Pa, Nowak RM, McCord J, et al.: B-type natriuretic peptide and clinical judgement in the emergency diagnosis of HF: analysis from breathing not properly multinational study. Circulation 2002, 106:416–422. CrossRef
- Maisel AS, Krishnaswamy P, Nowak RM, et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161–167. CrossRef
- Jernberg J, Stridsberg M, Venge P, et al.: N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002, 40:437–445. CrossRef
- Wang TJ, Larson MG, Levy D, et al.: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655–663. CrossRef
- Sadanandan S, Cannon C, Chekuri K, et al.: Association of elevated BNP levels with angiographic findings among patients with unstable angina and non-STEMI. J Am Coll Cardiol 2004, 44:564–568. CrossRef
- Omland T, Person A, Ng L, et al.: N terminal pro-B type natriuretic peptide and long term mortality in ACS. Circulation 2002, 106:2913–2918. CrossRef
- DeLemos JA, Marrow DA, Bentley JH, et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014–1021. BNP is established in this study to risk stratify patients with ACS in addition to clinical, ECG, and troponin tools. It suggests that cardiac neurohormonal activation, in addition to necrosis markers, is a feature of patients at high risk for death after ACS. CrossRef
- Sabatine MS, Morrow DA, de Lemos JA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Simultaneous assessment of troponin I, CRP, and B-type natriuretic peptide. Circulation 2002, 105:1760–1763. This prospective study demonstrated a multimarker strategy (troponin, BNP, and CRP) representing different pathophysiologic contributions to ACS. Each marker provided independent and incremental prognostic and risk stratification information. CrossRef
- James SK, Lindahl B, Siegbahn A, et al.: N-terminal pro brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A global utilization of strategies to open occluded arteries (GUSTO-IV) substudy. Circulation 2003, 108:275–281. CrossRef
- Newby LK, Storrow AB, Gibler WB, et al.: Bedside multimarker testing for risk stratification in chest pain units: the CHECKMATE study. Circulation 2001, 103:1832–1837. This is the seminal study showing the importance of a multimarker strategy (myoglobin, CKMB, troponin) to better risk stratify and identify high-risk patients with ACS when clinical history and ECGs may be nondiagnostic. Using all three biomarkers was superior for the identification of ACS patients at high risk.
- Wiviott SD, Cannon CP, Morrow DA, et al.: Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 2004, 109:580–586. CrossRef
- Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes
Current Cardiology Reports
Volume 7, Issue 4 , pp 263-269
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links